Table 2a.

Antigens in ACC.

Antigen	Positive	Negative
A new fused gene (MYB-NFIB)7	Highly +ve
C-Kit expression8	Highly +ve
Nerve growth factor9	+ve
Tyrosine kinase A9	+ve
Brain derived neurotrophic factor (BDNF)10	+ve
Heparanase, pRb2/p130, vascular endothelial growth factor, p63, Skp2, EGFR, c-kit, RUNX35	+ve
Survivin, R1-inducible coiled-coil 1, Geminin5	+ve
Maspin6	+ve
Muscle specific actin, smooth muscle actin or calponin5	+ve
MCM2 (mini-chromosome maintenance proteins)11	+ve
FAT tumor suppressor and transmembrane 4 superfamily membrane112	+ve
AP-2, macrophage erythroblast attacher12, versican13, and laminin-112	+ve
Sox 4, keratin 1712	+ve
Tumor-associated antigen L612	+ve
c-myb, located at 6q2212	+ve
Type 4 collagen13	+ve
Casein kinase 1, epsilon and frizzled-7 (members of the Wnt/β-catenin signaling pathway)8	+ve
CK8, CK14 and CK17 and for CK8, CK14, CK17 and CK1914	+ve
Carbohydrate antigen 19-9 (CA19-9)15		−ve
E-cadherin and alpha-catenin15	Increased as compared to basaloid scc
Ki-67 labeling index5	≥10%
Hepatocyte growth factor (HGF)9	+ve
CK(AE1/3), CK 34βE12, CK5/6, CK7, CK14, CK18, p63,5 CA19-9, c-KIT (CD117), PDGFRA, MUC1, and Ki-6714	+ve
CK8,7 CK20, desmin, S-100 protein, CD34, chromogranin, MUC2, MUC5AC and MUC614		−ve
CAM5.2, CK19, EMA, α-smooth muscle actin, p53, CD10, and synaptophysin14	+ve
CK5/CK714	+ve
CEA15		−ve
Vimentin and S-100 protein14	+ve
Chondroitin sulfate and basement membrane proteins12	+ve
No gene fusion of PLAG1 and mutation of CYLD (Germ-line mutation in cylindromatosis) in ACC tissues16	+ve
CD 4317	+ve